Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report

Submitted by Anonymous on

BackgroundRare epidermal growth factor receptor (EGFR) mutations have a low incidence, and their response to EGFR tyrosine kinase inhibitors (TKI) has not be Abstract Background: Rare epidermal growth factor receptor (EGFR) mutations have a low incidence, and their response to...

Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors

Submitted by Anonymous on

Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major therapeutic challenge in EGFR-mutant cancers. While third-generation covalent EGFR inhibitors successfully suppress the T790M-mediated resistance, acquisition of the C797S substitution abrogates irreversible drug binding and represents...

Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study

Submitted by Anonymous on

AbstractBackground Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) (EGFR-TKIs) show heterogeneous responses in patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR exon 19 deletion (E19del) mutations. This study evaluated the efficacy of second- and third-generation (2G/3G) EGFR-TKIs...

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study

Submitted by Anonymous on

Abstract RICTOR, a scaffold protein of the mTORC2 complex, regulates AKT signaling and has been implicated in tumor progression and therapy resistance across multiple cancers. However, the prognostic impact of RICTOR mutations in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma...

Stimulation of EGFR signaling in fibro-adipogenic precursors decreases adipogenesis in Duchenne muscular dystrophy

Submitted by Anonymous on

AbstractBackground Duchenne Muscular Dystrophy (DMD) is characterized by the formation of fibrosis and fat deposits that progressively replace muscle fibers, resulting in the loss of muscle function. Both fibrosis and adipogenesis are operated by fibroadipogenic precursors (FAPs), but the molecular...

Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study

Submitted by Anonymous on

Correction: Targeted Oncology (2026) 21:213-226 https://doi.org/10.1007/s11523-026-01203-6 In this article the author’s name Cheng-Ta Yang was incorrectly written as Chang-Ta Yang. In this article the ORCiD https://orcid.org/0000-0003-1846-1027 for Cheng-Ta Yang was inadvertently omitted. In Fig. 4 of this article at the...

Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling

Submitted by Anonymous on

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling by Yinghao WangYinghao...

Genetics-guided screening and biological validation identify zeylenol as a promising EGFR inhibitor in glioma

Submitted by Anonymous on

IntroductionTo overcome the high attrition rates in glioma drug discovery, this study established a systematic “Genetics-to-Drug” pipeline aimed at identifyi Abstract Introduction: To overcome the high attrition rates in glioma drug discovery, this study established a systematic “Genetics-to-Drug” pipeline aimed...

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation

Submitted by Anonymous on

AbstractIntroduction Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited treatment options. Phosphoglycerate kinase 1 (PGK1), with both glycolytic and kinase activities, has been implicated in tumor progression, but its therapeutic potential in ESCC remains unclear. Methods We...

Subscribe to Newsfeed